Close Menu

NEW YORK (GenomeWeb) – ERS Genomics today announced that it has non-exclusively licensed patents related to CRISPR-Cas9 genome-editing technology to Regeneron Pharmaceuticals for use in drug discovery and development.

Specific terms of the deal were not disclosed.

ERS was founded to provide broad access to the intellectual property, which is based on the research of Emmanuelle Charpentier from the Hannover Medical School in Germany and Umea University in Sweden.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.